槐耳颗粒联合TEC新辅助化疗对中晚期乳腺癌患者疾病控制率及血清HER2-ECD、TAP水平的影响

Effect of huaier granule combined with TEC neoadjuvant chemotherapy on disease control rate and serum HER2-ECD,TAP levels in patients with advanced breast cancer

目的探讨槐耳颗粒联合多西他赛+表柔比星+环磷酰胺(TEC)新辅助化疗对中晚期乳腺癌患者疾病控制率及血清人类表皮生长因子受体2胞外片段(HER2-ECD)、肿瘤异常蛋白(TAP)水平的影响。方法选取2013年4月至2016年6月中国医科大学附属盛京医院收治的中晚期乳腺癌患者94例进行前瞻性研究,以简单随机化法分为观察组(n=47)、对照组(n=47)。对照组予以TEC新辅助化疗,观察组予以TEC新辅助化疗联合槐耳颗粒治疗,均治疗12周。对比两组疗效、不良反应发生率与治疗前、治疗12周后细胞免疫功能指标(CD8+、CD4+、CD4+/CD8+)、血清HER2-ECD、TAP水平,治疗后随访3年,对比两组治疗后1年、2年、3年生存率。结果观察组治疗12周后疾病控制率高于对照组(P<0.05);治疗期间,观察组胃肠道反应、中性粒细胞减少、血小板减少、肝功能异常发生率低于对照组(P<0.05);观察组治疗12周后血清CD8+水平低于对照组,血清CD4+、CD4+/CD8+水平高于对照组(P<0.05);观察组治疗12周后血清HER2-ECD、TAP水平低于对照组(P<0.05);观察组治疗后3年生存率高于对照组(P<0.05)。结论槐耳颗粒联合TEC新辅助化疗治疗中晚期乳腺癌患者,可降低患者血清HER2-ECD、TAP水平,增强机体免疫功能,减轻毒副反应,提高远期生存率,疗效显著。

Objective To investigate the effect of huaier granule combined with docetaxel+epirubicin+cyclophosphamide(TEC)neoadjuvant chemotherapy on the disease control rate and the levels of extracellular fragment of human epidermal growth factor receptor 2(HER2-ECD)and tumor abnormal protein(TAP)in patients with advanced breast cancer.Methods From April 2013 to June 2016,94 patients with advanced breast cancer in Shengjing Hospital Affiliated to China Medical University were selected and randomly divided into observation group(n=47)and control group(n=47).The control group was treated with TEC neoadjuvant chemotherapy,and the observation group was treated with TEC neoadjuvant chemotherapy combined with huaier granules for 12 weeks.The curative effect,incidence of adverse reactions,cellular immune function indexes(CD8+,CD4+,CD4+/CD8+),serum HER2-ECD and TAP levels were compared before and 12 weeks after treatment.The patients were followed up for 3 years after treatment,and the 1-year,2-year and 3-year survival rates were compared between the two groups.Results After 12 weeks of treatment,the disease control rate of the observation group was higher than that of the control group,with statistically significant difference(P<0.05);during the treatment,the incidence of gastrointestinal reaction,neutropenia,thrombocytopenia and abnormal liver function of the observation group was lower than that of the control group,with statistically significant difference(P<0.05);after 12 weeks of treatment,the serum CD8+level of the observation group was lower than that of the control group,and the serum CD4+,CD4+/CD8+level was higher than that of the control group,with statistically significant difference(P<0.05);after 12 weeks of treatment,the serum levels of HER2-ECD and TAP in the observation group were lower than those in the control group,with statistically significant difference(P<0.05);the 3-year survival rate in the observation group was higher than that in the control group,with statistically significant difference(P<0.05).Conclusions Huaier granules combined with TEC neoadjuvant chemotherapy in patients with advanced breast cancer can reduce serum HER2-ECD,TAP levels,which can enhance the immune function of the body,reduce the toxic and side effects,improve the long-term survival rate,and have a significant effect.